FibroGen is a biopharmaceutical company whose fate is closely tied to its anemia treatment. Its price chart reflects its challenging path to commercialization and market competition, as well as its hopes for other drugs in its portfolio.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrotic diseases, and certain types of cancer. We classified it in "Other Pharma" due to its diversified portfolio. The chart below reflects general trends in the biotech sector.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrotic diseases, and certain types of cancer. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
FibroGen, Inc.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for the treatment of anemia and fibrosis.
FibroGen, Inc. is a biotech company. This chart highlights the sector's high volatility. Comparing it to FGEN, which focuses on treating anemia and fibrosis, helps assess its risks compared to more diversified pharmaceutical companies.
FibroGen is a biotech company developing drugs to treat anemia and fibrotic diseases. Its shares are driven by news of clinical trials and regulatory decisions. This high volatility is part of the market dynamics driven by hopes for new drugs.
For FibroGen, Inc., the year-over-year performance is a story of its struggles after regulatory setbacks. Its market cap change over the past 12 months reflects both sales of its anemia drug in China and Europe and, more importantly, progress in its oncology program and the development of a treatment for Duchenne muscular dystrophy, which is its bet for the future.
FibroGen, Inc. is a biopharmaceutical company focused on developing treatments for anemia and fibrotic diseases. This chart illustrates how its regulatory setbacks, competitive environment, and R&D potential impact its complex dynamics within the pharmaceutical sector.
FibroGen is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
FibroGen is a biopharmaceutical company with a commercial anemia treatment and oncology developments. Its monthly performance is the sum of two factors: quarterly sales of its drug and news from its clinical programs, particularly pamrelumab.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrotic diseases, and certain types of cancer. The chart below illustrates the overall dynamics of the pharmaceutical sector, which is used by investors to evaluate the potential of the company's diverse portfolio.
FibroGen, Inc. is a biotech company with drugs on the market and in development. Its dynamics are a mixture of stability from current sales and volatility from clinical trial news. This makes it less predictable than purely commercial companies but more resilient than startups.
FibroGen, a biopharmaceutical company, depends on sales of its anemia drug and news about other developments for the week. Sales data in China and Europe, as well as clinical trial results for other indications, create high volatility.
FibroGen and the entire biotech sector are moving against a backdrop of regulatory news and clinical trial data. Investor risk sentiment is a common driver for everyone. The chart will show how a company with an already approved product fares against this backdrop.
FibroGen and the entire biotech sector are moving against a backdrop of regulatory news and clinical trial data. Investor risk sentiment is a common driver for everyone. The chart will show how a company with an already approved product fares against this backdrop.
FibroGen's market capitalization chart is the financial valuation of a biotech company whose flagship anemia drug has encountered difficulties gaining approval in the US. It reflects both commercial successes in other countries and hopes for other drugs in development. Its dynamics tell a story about how regulatory setbacks can significantly impact a company's value.
FibroGen is a biopharmaceutical company developing drugs for the treatment of anemia, fibrosis, and cancer. Its market share reflects the value of its commercial product and development pipeline. The chart below shows how the market values this company after regulatory successes and setbacks.
FibroGen develops drugs to treat anemia and fibrotic diseases. The chart below shows the overall market capitalization of the entire sector. Its dynamics are a story of ups and downs. FibroGen, like many biotech companies, has experienced both successes and failures in clinical trials.
The biotechs visible on the chart are facing setbacks. FibroGen develops drugs to treat anemia and fibrotic diseases. Its market capitalization reflects both the approval of its anemia drug and failures in clinical trials for other, more significant indications.
FibroGen's book value represents the financial backing for its development of drugs for fibrotic and anemic conditions. The chart reflects the value of its R&D centers and manufacturing contracts, which support the development and commercialization of its lead drug for the treatment of anemia in chronic kidney disease.
FibroGen, a biopharmaceutical company, has both commercial and developmental products. Its stake in the sector's assets lies in its R&D centers and manufacturing facilities. This hybrid base supports both current sales and future research.
FibroGen, Inc. is a biopharmaceutical company. Its model is moderately capital-intensive. In addition to R&D, it has a commercial infrastructure for its anemia drug. Compared to the pharmaceutical sector, it is more "heavy" than purely R&D companies.
FibroGen's assets extend beyond research and development, leveraging deep expertise in growth factors that regulate red blood cell production and fibrosis. The company's balance sheet reflects the value of its approved drug and research platforms. The chart shows the capital behind this leader in its biological niche.
FibroGen is a biopharmaceutical company with an approved drug and a pipeline of developments. Its market capitalization is a complex combination of current sales, the potential of new drugs, and the risks associated with clinical trials and competition.
FibroGen is a biopharmaceutical company with approved products and a pipeline of developments. Its valuation is a balance between current sales and future potential. This chart shows how the market views its commercial success and the risks associated with new research.
FibroGen is a biopharmaceutical company developing drugs to treat anemia and fibrotic diseases. Its market capitalization is based on the potential of its scientific developments and already approved products. This chart demonstrates how much a biotech company's valuation can exceed its book value thanks to its intellectual property.
FibroGen is a biopharmaceutical company with approved products and a number of developments. Debt financing can be used for several purposes: to support the commercialization of existing drugs and to finance costly clinical trials of new candidates in its pipeline.
FibroGen, Inc. is a biopharmaceutical company with an approved product and other candidates in development. This chart shows how the company manages its balance sheet post-commercialization, using revenue and capital to fund expensive research in other areas, such as oncology and fibrotic diseases.
FibroGen, Inc., a biopharmaceutical company with products on the market and in development, has significant expenses for both sales and research. This chart shows its debt load. Even for a company with revenue, high debt can become a problem if sales fail to meet expectations or key drugs in development fail.
FibroGen is a biopharmaceutical company focused on treating anemia, fibrosis, and cancer. This chart compares its debt, raised to fund a wide range of clinical programs, to the overall market capitalization of the pharmaceutical sector. It helps assess how the company manages risk across its diversified portfolio.
FibroGen is a biopharmaceutical company with commercialized products and new developments in its pipeline. The chart shows how the company balances the use of debt for marketing existing drugs and funding R&D. This reflects its transition from a purely research-based to a commercial stage, which is comparable to other players in the industry.
This chart for FibroGen, a biopharmaceutical company, tells the story of its struggle to commercialize its lead drug. The price-to-earnings ratio shows how investors view its prospects after mixed results and regulatory decisions. The price-to-earnings ratio reflects sales news and data from other developments.
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for FibroGen. Comparison with this metric helps investors understand how the market views the company's drug prospects relative to competitors. A below-average valuation may indicate doubts about their commercial potential or patent risks.
FibroGen is a biopharmaceutical company that has developed a drug to treat anemia in patients with chronic kidney disease. It also has developments in oncology. This chart shows sentiment in the biotech sector. It helps understand how the commercial success of its lead drug and progress in other clinical programs impact the company's valuation.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrosis, and cancer. This chart reflects analyst expectations for sales of its currently approved drugs in various regions, as well as the success of its clinical programs. It provides a comprehensive assessment of its current and future pipeline.
%20P%2FE%20FibroGen%2C%20Inc.&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-FibroGen-Inc. "Chart of the company's future (projected) P/E FibroGen, Inc.")
FibroGen is a biopharmaceutical company focused on developing treatments for anemia, fibrosis, and cancer. This chart compares its future profitability expectations with those of the pharmaceutical industry. It helps understand how the market views its approved drug for the treatment of anemia in chronic kidney disease and its research programs in other areas.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
FibroGen is a biopharmaceutical company focused on drugs for the treatment of anemia and fibrotic diseases. This chart shows the company's overall risk appetite. FibroGen's success depends on the commercial success of its already approved drugs and the clinical trial results of its new ones. It's a story driven by science and sales.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
FibroGen is a biopharmaceutical company developing and commercializing drugs for the treatment of anemia in patients with chronic kidney disease and for the treatment of fibrotic diseases. This chart shows financial results dependent on the success of its approved drugs and progress in clinical trials.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrosis, and cancer. Its lead product helps the body produce red blood cells. This chart shows the overall financial picture of the pharmaceutical industry, reflecting how companies are bringing new treatments to market for a wide range of chronic and serious diseases.
FibroGen is a biopharmaceutical company developing treatments for anemia and fibrotic diseases. Demand for their products is driven by medical needs. However, the commercial success of an approved drug may depend on market acceptance and competition, as well as the ability of healthcare systems to pay.
FibroGen is a biopharmaceutical company whose lead drug is designed to treat anemia in patients with chronic kidney disease. Its future depends on sales growth for this drug and the success of its other developments. This chart shows how analysts assess the commercial potential of its key product.
%20profit%20of%20the%20company%20FibroGen%2C%20Inc.&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-FibroGen-Inc. "Graph of future (projected) profit of the company FibroGen, Inc.")
FibroGen is a biopharmaceutical company developing drugs for the treatment of anemia, fibrotic diseases, and cancer. This chart shows forecasts for the biotech sector. FibroGen's profitability depends on the commercial success of its already approved anemia drug and on the progress of its innovative candidates for the treatment of other serious conditions in clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
FibroGen, Inc. is a biopharmaceutical company developing treatments for anemia and fibrotic diseases. Its success depends on the approval and commercialization of its key products. This earnings forecast chart influences the overall investment climate and valuation of companies whose future revenues depend on several promising, but not yet fully developed, drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrosis, and cancer. This chart shows how the market values its revenue, which may include both sales of approved products and payments from partners. It reflects the commercial success and potential of its developments.
FibroGen is a biopharmaceutical company focused on developing drugs for the treatment of anemia, fibrosis, and cancer. Its first commercial product is designed to treat anemia in chronic kidney disease. This chart shows the average biotech valuation, helping to understand how the market values both FibroGen's commercial products and clinical development.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrosis, and cancer. Its revenue is generated from sales of its approved drug and partner fees. This chart helps assess the market perception of the company's current revenue and the potential of its research programs.
FibroGen develops drugs to treat anemia, fibrotic diseases, and cancer. This chart shows how investors assess future revenue from its currently approved drug and the potential of other candidates in the pipeline. These trends depend on commercial success and clinical trial results.
%20P%2FS%20FibroGen%2C%20Inc.&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-FibroGen-Inc. "The graph of the company's future (projected) P/S FibroGen, Inc.")
FibroGen is a biopharmaceutical company focused on treatments for anemia and fibrotic diseases. This chart compares the company's estimated future sales with its industry. It reflects the market's assessment of the commercial potential of its current and future drugs.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrosis, and cancer. This chart shows overall revenue expectations, as FibroGen works to address serious medical problems. Success in its drugs across various therapeutic areas could create several new multibillion-dollar revenue streams.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
FibroGen is a biopharmaceutical company marketing a drug for the treatment of anemia in patients with chronic kidney disease. Revenue, shown in this chart, is generated through royalties and payments from partners such as AstraZeneca and Astellas, which market the drug globally.
FibroGen is a biopharmaceutical company that discovers, develops, and commercializes drugs to treat serious diseases, such as anemia in chronic kidney disease and cancer. This chart illustrates the dynamics of the pharmaceutical sector, where companies working on treating chronic conditions have the potential to create blockbusters.
FibroGen, Inc. is a biopharmaceutical company focused on developing treatments for anemia, fibrosis, and cancer. Its success depends on clinical trial results and partnerships. Gross revenue growth, reflected in this chart, improves the investment climate, allowing companies like FibroGen to raise capital and enter into favorable licensing agreements.
FibroGen, Inc. is a biopharmaceutical company focused on drugs for the treatment of anemia in chronic kidney disease and the treatment of fibrotic diseases. This chart reflects analyst expectations for sales of its existing products and progress in developing new ones.
%20sales%20of%20the%20company%20FibroGen%2C%20Inc.&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-FibroGen-Inc. "Schedule of future (projected) sales of the company FibroGen, Inc.")
FibroGen is a biopharmaceutical company developing drugs for the treatment of anemia in chronic kidney disease, as well as for the treatment of fibrotic diseases and cancer. This chart shows forecasts for the pharmaceutical sector, providing context for evaluating FibroGen's diversified development portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
FibroGen, a biopharmaceutical company, sees this chart as an indicator of the overall health of the sector. The optimistic economic forecasts reflected here are fueling increased R&D funding and M&A deals, creating a favorable environment for the development and commercialization of their research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
FibroGen is a biopharmaceutical company with approved and marketed drugs. This chart shows how successfully the company has transitioned from research to commercialization. It reflects the percentage of drug sales revenue retained by the company as net profit after all expenses.
FibroGen is a biopharmaceutical company focused on the treatment of anemia, fibrosis, and cancer. For a company with multiple late-stage programs, efficiency lies in the careful allocation of resources between the commercialization of approved drugs and continued R&D.
FibroGen is a biopharmaceutical company that discovers and develops drugs for the treatment of anemia, fibrosis, and cancer. Based on overall profitability, FibroGen has both commercial products and pipelines. Their profitability depends on sales of existing drugs and the success of their clinical pipeline.
FibroGen is a biopharmaceutical company developing drugs to treat anemia and fibrotic diseases. This graph shows its large team, reflecting its status as a company with an approved product and an extensive research pipeline.
FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrotic diseases, and cancer. This chart shows the percentage of scientists and clinicians FibroGen attracts in its therapeutic areas. This is a measure of its scientific potential and the breadth of its research programs.
FibroGen is a biopharmaceutical company developing and commercializing drugs for the treatment of anemia and fibrotic diseases. Its staff includes both scientists and a commercial team. This graph shows its operational activities. The staff dynamics reflect the life cycle of its products, from research to commercialization.
FibroGen is a biopharmaceutical company focused on the treatment of anemia and fibrotic diseases. Its growth and HR strategy are driven by the success of its drug development and commercialization. This chart shows the overall picture, but for FibroGen, regulatory decisions and drug sales trends are more important.
FibroGen is a biopharmaceutical company with products on the market. This metric reflects both the value of its intellectual property and the availability of its commercial infrastructure. The graph shows the balance between the value of R&D and sales effectiveness.
%20of%20the%20company%20FibroGen%2C%20Inc.%20(FGEN)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-FibroGen-Inc.-FGEN "Chart of market capitalization per employee (in thousands of dollars) of the company FibroGen, Inc. (FGEN)")
FibroGen, Inc. is a biopharmaceutical company developing treatments for anemia, fibrosis, and cancer. Its valuation is dependent on the success of its current and future drugs. This chart compares investor confidence in its scientific platform and product portfolio per employee compared to other biotech companies.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
FibroGen is a biopharmaceutical company with both commercialized products and drugs in development targeting anemia, fibrosis, and cancer. This chart shows how the market values a company with a mixed model, where revenue from existing products funds risky but potentially highly valuable research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
FibroGen is a biopharmaceutical company with an approved drug (Roxadustat, outside the US) for the treatment of anemia, as well as R&D in fibrosis and cancer. This chart shows how successfully the company commercializes its drug (through partners) and funds its expensive R&D per employee.
%20Chart%20FibroGen%2C%20Inc.%20(FGEN)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-FibroGen-Inc.-FGEN "Company Profit Per Employee (in thousands of dollars) Chart FibroGen, Inc. (FGEN)")
FibroGen (FGEN) is a biopharmaceutical company with both commercialized products (an anemia drug) and R&D candidates (for example, for cancer treatment). This chart reflects a hybrid model. It shows how the company generates revenue from current sales (based on its sales force) while simultaneously investing in its R&D team to develop future products.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
FibroGen is a biopharmaceutical company with both approved drugs (for anemia) and development projects (in oncology). It operates on a hybrid model. This chart shows the balance between profits from existing drugs and the enormous R&D costs of new ones. The profit per employee here is the net result of this complex financial alchemy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
FibroGen is a biopharmaceutical company developing drugs to treat anemia and fibrotic diseases. This chart shows the commercial success of their already approved drugs. High revenue per employee indicates that their drugs are in demand and that the company effectively manages their production and sales.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-FibroGen-Inc.-FGEN "Sales chart per company employee FibroGen, Inc. (FGEN)")
FibroGen is a biopharmaceutical company developing drugs to treat anemia in chronic kidney disease (Roxadustat) and fibrotic diseases. This chart shows the average revenue per employee in the sector. It helps assess how productive FibroGen's R&D and commercial (through partners) model is compared to other biotech companies.
FibroGen, Inc. (FGEN) is a biopharmaceutical company with an approved drug (Roxadustat) for the treatment of anemia in chronic kidney disease (approved in Europe and China, but not in the US). This chart shows how well the company generates revenue (royalties) from sales of its drug outside the US.
FibroGen is a biopharmaceutical company whose key anemia drug (Roxadustat) failed to receive FDA approval in the US due to safety concerns. The chart shows the number of investors betting that the company will not recover from this failure, and that its other drug candidates (such as for MASH) will also fail in the clinic.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-FibroGen-Inc.-FGEN "Short Shares Chart for the Company FibroGen, Inc. (FGEN)")
FibroGen is a biotech company focused on drugs for anemia and fibrotic diseases. This indicator measures the overall skepticism in the pharmaceutical industry. When it is high, it indicates that investors generally do not believe in the success of clinical trials or anticipate funding problems, which poses a risk to the entire industry.
FibroGen (FGEN) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like FGEN in favor of safer assets.
FibroGen, Inc. develops drugs to treat anemia and fibrotic diseases. The company's shares are highly dependent on regulatory decisions and clinical trial data. This chart tracks how the market reacts to these events, showing "overheating" (above 70) on positive news or "oversold" (below 30) following FDA rejections or failed trials.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-FibroGen-Inc.-FGEN "RSI 14 indicator chart for the company's stock FibroGen, Inc. (FGEN)")
FibroGen is a biotech company specializing in the treatment of anemia associated with chronic kidney disease (Roxadustat) and fibrotic diseases. This chart measures the overall momentum of the biotech sector. It helps separate FGEN volatility related to regulatory decisions from the overall industry trend.
For FibroGen, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
FibroGen is a biotech company whose key product is a drug for the treatment of anemia in patients with CKD. The company is also developing therapies for fibrotic diseases. This chart shows the average 12-month analyst forecast. Their target price reflects a complex assessment of the competition in anemia treatments and R&D risks.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FGEN-FibroGen-Inc. "A chart showing analyst consensus forecasts for the expected stock price. FGEN (FibroGen, Inc.)")
FibroGen is a biopharmaceutical company whose key drug, Roxadustat, is designed to treat anemia in patients with CKD. This chart shows the difference between the market valuation and the consensus estimate. It indicates whether experts believe the drug can achieve approval and commercial success outside of China.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FGEN-FibroGen-Inc. "A chart showing the difference between the consensus forecast and the actual stock price. FGEN (FibroGen, Inc.)")
FibroGen is a biotech company whose flagship anemia drug (Roxadustat) was approved globally but (critically) failed to be approved in the US. It is now focusing on fibrosis R&D. This chart shows analysts' overall expectations for the entire pharmaceutical sector. It reflects whether experts believe the company can "reboot."
FibroGen is a biotech company specializing in drugs for the treatment of anemia (associated with kidney disease) and fibrotic diseases. This chart shows overall risk appetite. For FibroGen, a company with a history of regulatory setbacks, overall market optimism is important for funding, but news from the FDA and partners carries far more weight.
FibroGen (FGEN) is a biotech company that has suffered a major blow. Their flagship anemia drug (Roxadustat) was approved globally but rejected in the US (FDA). This chart is a summary indicator of their Plan B. It weighs their stable international royalties against their desperate attempts to salvage their R&D pipeline in oncology and fibrosis.
FibroGen (FGEN) is a biopharmaceutical company known for its drug Roxadustat (Evrenzo) for the treatment of anemia caused by chronic kidney disease. They are also developing therapies for fibrotic diseases. The chart shows the average index for the segment. This helps investors assess how FibroGen compares to the pharmaceutical industry average, especially after regulatory challenges in the US.
FibroGen is a biopharmaceutical company developing drugs for anemia, fibrosis, and cancer. It has experienced setbacks with its key drug. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this "fallen" biotech company, struggling to recover, compares to overall economic trends.
